Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ (marstacimab-hncq) for routine ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...
Pfizer has won European Commission approval of its Hympavzi treatment for certain patients with the blood-clotting disorder hemophilia. The New York drugmaker on Wednesday said the approval covers ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Based on these results, the FDA approved this drug for a similar indication last month ... The latest decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in ...